Grass Pollen Allergy
12
2
2
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
25%
3 trials in Phase 3/4
10%
1 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (12)
Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study
Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction
GRASS (Grass MATA MPL Real-world Assessment Study)
A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
Phase II Study of Grass Pollen Allergy Vaccine BM32
Regulatory T-cells After Subcutaneous Immunotherapy
Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis
Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis
Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture
Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy
A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment